Altering the natural history of acute myeloid leukemia (AML) in unfit and older patients has proved a highly challenging hurdle. despite several decades of concerted clinical trial effort. The arrival of venetoclax (VEN) to the clinical stage represents the most important therapeutic advance to date for older patients with AML. In this review. https://www.taqueriamedina.com/product-category/headwear/